Antibody in asthma treatment
Correct Answer: Omalizumab
Description: Omalizumab o Omalizumab is an anti IgE agent approved by the (FDA)
for use in patients age 12 and above with moderate to severe persistent allergic asthma with
: - An IgE level of30-700 lu/ml. Positive allergen skin or specific IgE tests to a perenmial allergen and Incomplete symptom control
with inhaled glucocorticoid treatment. o Omalizumab is administered by “subcutaneous injecon ” every mo to four weeks in a dose that
is determined by- body weights and the level of serum IgE.
o Omalizumab produces 25% reduction in rate of asthma exacerbations.
The response to omalizumab therapy is variable and dif icult to predict with overall response rates in patients with moderate to severe asthma averaging 30-50%.
A minimum of 12 weeks of treatment is necessary to determine the efficacy 1 ofanti-IgE theraphy
Category:
Medicine
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now